Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) announced that Ascendis has entered into a US$150 million capped synthetic royalty funding agreement with Royalty Pharma based on US net SKYTROFA revenue.
Latham & Watkins LLP represents Ascendis Pharma A/S in the transaction. The royalty funding agreement was led by partners Jekkie Kim and Haim Zaltzman, with associate Billy Wu. The corporate team was led by partners Mark Roeder and John Williams, with associates Tess Bloom and Tyler Israel. Advice was also provided on finance matters by partner Elizabeth Oh; and on tax matters by partner Eric Cho, with associate Sam Yang.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
